Appears on
Articles3
China Compliance Update: Life Sciences — Spring 2026
In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry. In addition to long-standing priorities, such as fraud against China’s state-run medical insurance program, regulators appear to be paying greater attention to investigator-initiated studies and patient programs in 2026. This Advisory summariz
China Compliance Update: Anti-Corruption — Spring 2026
Anti-corruption continued to be a major focus for Chinese regulators in 2026, with the Supreme People’s Court publishing its first new judicial interpretations of China’s corruption and bribery regulations in a decade. Official statistics provided further evidence of regulators’ continued emphasis on both administrative and criminal anti-corruption enforceme
China Finalizes Regulations for Pharmaceutical Sales Representatives
China’s 2026 Management Measures for Medical Representatives significantly expand pharmaceutical compliance obligations by imposing stricter oversight on medical representatives, Marketing Authorization Holders, and third-party sales organizations. The regulations strengthen anti-bribery and anti-fraud enforcement, require enhanced monitoring of promotional